ReviewInternational journal of nanomedicine2026
Recent Advances in Nanozymes Toward Diabetic Foot Ulcers.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcers (DFUs) are one of the most serious and intractable complications of diabetes, caused by oxidative stress due to hyperglycemia, chronic inflammation, and repeated infections. Conventional treatments such as insulin therapy do not improve the pathological wound microenvironment, resulting in slow healing and a high rate of recurrence. Nanozymes, with superior catalytic stability, tuneable enzyme-like activities, and multifunctional synergy, have emerged as a promising therapeutic strategy. Nanozymes that imitate natural enzymes such as glucose oxidase, peroxidase, catalase, and superoxide dismutase can actively remodel the DFUs microenvironment via glucose depletion, dynamic regulation of reactive oxygen species, disruption of biofilm, suppression of inflammation, and oxygen generation. These integrated functions can help wounds heal faster, and they can promote angiogenesis and tissue regeneration. This review discusses recent advances in catalytic mechanisms and therapeutic applications of nanozymes for DFUs management, with special attention paid to the microenvironment-responsive systems, hydrogel-based composites, and synergistic photothermal or drug delivery platforms. Lastly, the current issues of biosafety, catalytic efficiency, and target accuracy are mentioned, followed by future directions for clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.